MannKind Receives FDA Approval for Afrezza Label Update
ByAinvest
Monday, Jan 26, 2026 6:47 am ET1min read
MNKD--
MannKind has announced that the FDA has approved an update to the Prescribing Information for Afrezza Inhalation Powder. The updated labeling revises recommendations for starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. The change is based on modeling data and in vivo results from two clinical trials. The update aims to provide clearer guidance for healthcare providers transitioning patients to inhaled insulin.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet